Intellia Therapeutics has reported positive three-year follow-data from the ongoing Phase 1/2 trial of lonvo-z (formerly known as NTLA-2002) in...
New clinical data from Allogene Therapeutics' Phase 1 TRAVERSE trial reveals durable responses in patients with heavily pre-treated advanced renal...
Prime Medicine has reported promising initial clinical data from the first-ever trial of a prime-editing therapeutic candidate, showing that a single...
This week's clinical update includes FDA RMAT designation to Beam Therapeutics' BEAM-302 for the treatment of alpha-1 antitrypsin deficiency as well...
Durham-based Precision BioSciences has received IND clearance for PBGENE-HBV, making it the first investigational in vivo gene-editing therapy to...
Eight months after dosing the first patient with BEAM-302, Beam Therapeutics has shared exciting safety and efficacy data indicating that a...
YolTech Therapeutics reports positive clinical data for the first in vivo gene-editing therapy in primary hyperoxaluria type 1, Precision BioSciences...
The Bahrain Oncology Centre announced a major milestone on Sunday with the successful administration of CASGEVY - the world's only approved therapy...
